Navigation Links
US Cancer Vaccine Market Analysis
Date:9/17/2012

can be expected to come up soon with promising candidates, such as Lucanix and Stimuvax having entered phase 3 trials.

The report also covers the FDA's vaccine approval process and its guidance to the industry for developing therapeutic cancer vaccines. The therapeutic vaccines currently account only for about 15% share in the US cancer vaccine market but this share can be expected to increase drastically post 2016 with such high focus on developing therapeutics for other cancer types.

The report "US Cancer Vaccine Market Analysis", is an outcome of an extensive research and prudent analysis of the cancer vaccine market in the world and in US. It provides an effective analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Further, the report provides an in-depth analysis on the pipeline cancer vaccines in phase 1-4 clinical stages for most prevalent cancers in US. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines for clinical proceedings of cancer therapeutic vaccines has also been provided. The report also provides competitive analysis of the promising players in the market along with their key strategies to increase their penetration in the market.

1. Analyst View2. Research Methodology3. Cancer Statistics by Demographics3.1 Prevalence, Incidences and Mortality (2008-2016)3.2 Leading States by Incidence3.3 Leading Cancers by Incidence3.3.1 Male Cancer Incidences3.3.2 Female Cancer Incidences3.3.3 Age-Group4. Cancer Vaccines Market Outlook4.1 Market Analysis and Segmentation4.2 Key Product Analysis4.2.1 Provenge4.2.1.1 Market Analysis4.2.1.2 Restraints4.2.2 HPV Vaccine4.2.2.1 Gardasil4.2.2.1.1 Market Analysis4.2.2.1.2 Restraints4.2.2.2 Cervarix4.2.2.2.1 Market Analysis4.2.2.2.2 Restraints4.2.3 HBV Vaccines4.2.3.1 Market Analysis4.2.3.2 Market Re
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
2. Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
3. Prostate Cancer: The End of Life As Men Know It?
4. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
5. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
6. Frost & Sullivan Lauds IncellDx for Developing a Novel, Non-invasive Method for Cervical Cancer Testing
7. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
8. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. Urologists And Henry Schein Team Up To Urge Families To Put A Prostate Cancer Check-Up On The Back To School List For Dad
10. The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
11. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...
... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...
Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:3/5/2015)... East Providence, RI (PRWEB) March 05, 2015 ... for a third year in a row to support the ... cancer. The donation covered the purchase of the ‘Think ... Out’ game against Big East Conference opponent DePaul University at ... is pleased to continue our support of the PC women’s ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 In honor ... to shatter myths about drug and alcohol abuse in ... released a Fact Sheet with information on some of ... in 2010 by the National Institute on Drug Abuse, ... alcohol aims to counteract the illusions that teens and ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Nutrition Leaders, ... products, is pleased to offer reformulated Millennium 500 Creatine ... Millennium 500 is a German grade creatine supplement that ... promote muscle recovery, and aid with overall strength gains ... that acts as a reserve energy source in the ...
Breaking Medicine News(10 mins):Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2
... a study done by Kate Rittenhouse-Olson, Ph.D., the monoclonal antibody ... shown to extend// significantly the survival of mice with human ... antibody inhibits the cancer's spread to the lungs in the ... study were published in the November 2006 issue of Journal ...
... of height which happens as people catch up with age is ... which could have major repercussions on health, increasing the chances of ... of about 3 centimeters or more in height of men as ... compared to men who lose less than a centimeter. This risk ...
... Researchers from University of Queensland believe that the conotoxins ... treatment for sufferers from chronic pain//. This treatment could ... ,Researchers say that the toxin, snail uses ... the severe side effects usually caused by other pain ...
... say that they are not abandoning their quest of finding ... the death of new cholesterol drugs manufactured// by Pfizer. Reducing ... cardiology in recent years, but boosting its counterpart, HDL, also ... market the new drug with Lipitor, a cholesterol-lowering statin that ...
... will now be made more easily available to critically ill ... proposition that will enable patients// who are extremely ill to ... other options. ,The FDA has announced that they ... drugs to be made available to needy individuals .They will ...
... nosed, bleary- eyed Britons, relief from hay fever may ... pill, designed to prevent// allergic reactions like a running nose, itching ... ,The vaccine pill contains small amounts of Timothy grass pollen; main ... weeks before hay fever season. ,This pill follows the ...
Cached Medicine News:Health News:Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies 2Health News:Revolutionary Pill Promises Relief for Hay Fever Sufferers 2
For the quantitative in vitro determination of Transferrin in human serum...
For the quantitative in vitro determination of Transferrin in Serum...
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: